Understanding the Role of Targets and Pathways in the Treatment of Chronic Lymphocytic Leukemia
Click here for continuing education information.
After reviewing the articles in this supplement, click on the "How to Earn Credit" link at the bottom of the page for instructions on how to take the learning assessment, complete the evaluation form, and earn credit.
This CME/CE/CPE accredited supplement is jointly provided by:
Faculty
Christopher Arp, PharmD, Levine Cancer Institute—Carolinas HealthCare System, Department of Pharmacy
Kristan Augustin, PharmD, BCOP, Barnes-Jewish Hospital, Department of Pharmacy
Hani M. Babiker, MD, University of Arizona College of Medicine, Translational Genomics Research Institute, and University of Arizona Cancer Center
Andrew Garcia, PharmD, The University of Arizona Cancer Center
Ashley E. Glode, PharmD, BCOP, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Amy Goodrich, MSN, CRNP, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Alyssa Hinchman, PharmD, The University of Arizona Cancer Center
Lindsay Hladnik, PharmD, BCOP, Washington University in Saint Louis School of Medicine, Department of Medicine
Nadia Khan, MD, Fox Chase Cancer Center
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, The University of Arizona Cancer Center
Ali McBride, PharmD, BCOP, The University of Arizona Cancer Center
Lisa Nodzon, PhD, ARNP, AOCNP®, Department of Malignant Hematology, Moffitt Cancer Center
Javier Pinilla-Ibarz, MD, PhD, Department of Malignant Hematology, Moffitt Cancer Center
Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, Fox Chase Cancer Center
Nina Wagner-Johnston, MD, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This activity is supported by unrestricted educational grants from
Gilead Sciences Inc. and Pharmacyclics LLC, an AbbVie Company and
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Editorial
A Letter From the Guest Editors
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, and Ali McBride, PharmD, BCOP
Read MoreContinuing Education
Chronic Lymphocytic Leukemia in 2018: What the Advanced Practitioner in Oncology Needs to Know
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, and Ali McBride, PharmD, BCOPRead MoreReview Article
Scientific Advances in the Diagnosis and Risk Stratification of Chronic Lymphocytic Leukemia
Amy Goodrich, MSN, CRNP, and Nina Wagner-Johnston, MDRead MoreReview Article
Monoclonal Antibodies in Chronic Lymphocytic Leukemia
Lindsay Hladnik,(1) PharmD, BCOP, Kristan Augustin,(2) PharmD, BCOP, and Christopher Arp,(3) PharmDRead MoreReview Article
Small Molecules in Chronic Lymphocytic Leukemia: Novel Targets, New Challenges
Sandra E. Kurtin, PhDc, ANP-C, AOCN®, and Ali McBride, PharmD, BCOPRead MoreReview Article
Emerging Therapies in Chronic Lymphocytic Leukemia: Current Trials
Ashley E. Glode, PharmD, BCOP, and Hani M. Babiker, MDRead MoreReview Article
Risk-Adapted Treatment Strategies for Chronic Lymphocytic Leukemia
Lisa Nodzon, PhD, ARNP, AOCNP®, and Javier Pinilla-Ibarz, MD, PhDRead MoreReview Article
Supportive Care and Management of Treatment-Emergent Adverse Events in Chronic Lymphocytic Leukemia
Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, and Nadia Khan, MDRead MoreReview Article
The Older Adult Living With Chronic Lymphocytic Leukemia: Implications for Oncology Providers, Patients, and Caregivers
Sandra E. Kurtin, PhDc, ANP-C, AOCN®Read MoreAppendix
Appendix
Compiled by Ali McBride, PharmD, BCOP, Andrew Garcia, PharmD, and Alyssa Hinchman, PharmDRead MoreContinuing Education
How to Earn Credit
Read More